TAKTakedaFinished
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 354 (final count)
- Started
- Jan 10, 2020
- Main results expected
- Sep 22, 2026
- Fully finished
- Sep 22, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measured over: Up to approximately 40 months after the first participant is randomized
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04129502 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC